Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 6/20 | 0.71 |
| ▸ | CASP3 | P42574 | 2/20 | 0.62 |
| ▸ | CTSL | P07711 | 6/20 | 0.58 |
| ▸ | CTSD | P07339 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | ECE1 | P42892 | 1/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14341580 | 1.00 | CTSB (0.71) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL5133312 | 1.00 | CTSB (0.71) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL23926088 | 1.00 | CTSB (0.71) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL8586819 | 0.96 | CTSB (0.65) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL10084536 | 0.96 | CTSB (0.65) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL10084585 | 0.93 | CTSB (0.62) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL7808000 | 0.93 | CTSB (0.62) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL7806376 | 0.93 | CTSB (0.62) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL10084583 | 0.93 | CTSB (0.62) | CTSBCASP3CTSLCTSDCTSS | |
| SCHEMBL621233 | 0.92 | CTSB (0.61) | CTSBCASP3CTSLCTSDCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4135660-A1 | COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11219670-B2 | Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| WO-2021211808-A1 | COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS | ATOSSA THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021072212-A1 | PROTEASOME INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2016057041-A1 | COMPOSITIONS AND METHODS FOR PRESERVING PLATELET FUNCTION | BIOVEC TRANSFUSION, LLC (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016037157-A2 | TARGETING CAPN9/CAPNS2 ACTIVITY AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF MYOFIBROBLAST DIFFERENTIATION AND ASSOCIATED PATHOLOGIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20150056604-A1 | COMPOSITIONS AND METHODS FOR PRESERVING PLATELET FUNCTION | BIOVEC TRANSFUSION, LLC | 2015-02-26 | — | — | US | disclosed |
| EP-0503561-B1 | Method for the diastereoselective reductive pinacol coupling of homochiral alpha aminoaldehydes | HOECHST AG (DE) | 1998-10-28 | — | — | EP | disclosed |
| US-5519113-A | Process for the diastereoselective reductive pinacol coupling of homochiral α-aminoaldehydes | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-05-21 | — | — | US | disclosed |
| EP-0503561-A2 | Method for the diastereoselective reductive pinacol coupling of homochiral alpha aminoaldehydes | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11219670-B2 | Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies | CAPN9, CAPNS1, CAPN2 | CTSB 367/4885CASP3 2284/4885CTSL 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.